|
1
|
Ketabi M, Andishgar A, Fereidouni Z, Sani
MM, Abdollahi A, Vali M, Alkamel A and Tabrizi R: Predicting the
risk of mortality and rehospitalization in heart failure patients:
A retrospective cohort study by machine learning approach. Clin
Cardiol. 47:e242392024. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xu X and Xu Z; Association between
phenotypic age the risk of mortality in patients with heart
failure: A retrospective cohort study. Clin Cardiol. 47:e243212024.
View Article : Google Scholar
|
|
3
|
Pratley R, Guan X, Moro RJ and do Lago R:
Chapter 1: The burden of heart failure. Am J Med. 137(2S): S3–S8.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mulugeta H, Sinclair PM and Wilson A:
Prevalence of depression and its association with health-related
quality of life in people with heart failure in low- and
middle-income countries: A systematic review and meta-analysis.
PLoS One. 18:e02831462023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shahim B, Kapelios CJ, Savarese G and Lund
LH: Global public health burden of heart failure: An updated
review. Card Fail Rev. 9:e112023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Emmons-Bell S, Johnson C and Roth G:
Prevalence, incidence and survival of heart failure: A systematic
review. Heart. 108:1351–1360. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Caturano A, Vetrano E, Galiero R,
Salvatore T, Docimo G, Epifani R, Alfano M, Sardu C, Marfella R,
Rinaldi L and Sasso FC: Cardiac hypertrophy: From
pathophysiological mechanisms to heart failure development. Rev
Cardiovasc Med. 23:1652022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Castiglione V, Aimo A, Vergaro G, Saccaro
L, Passino C and Emdin M: Biomarkers for the diagnosis and
management of heart failure. Heart Fail Rev. 27:625–643. 2022.
View Article : Google Scholar :
|
|
9
|
Bozkurt B, Coats AJS, Tsutsui H,
Abdelhamid CM, Adamopoulos S, Albert N, Anker SD, Atherton J, Böhm
M, Butler J, et al: Universal definition and classification of
heart failure: A report of the heart failure society of America,
heart failure association of the European society of cardiology,
Japanese heart failure society and writing committee of the
universal definition of heart failure: Endorsed by the Canadian
heart failure society, heart failure association of India, cardiac
society of Australia and New Zealand, and Chinese heart failure
association. Eur J Heart Fail. 23:352–380. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Triposkiadis F, Xanthopoulos A, Parissis
J, Butler J and Farmakis D: Pathogenesis of chronic heart failure:
Cardiovascular aging, risk factors, comorbidities, and disease
modifiers. Heart Fail Rev. 27:337–344. 2022. View Article : Google Scholar
|
|
11
|
Huang K, Wu H, Xu X, Wu L, Li Q and Han L:
Identification of TGF-β-related genes in cardiac hypertrophy and
heart failure based on single cell RNA sequencing. Aging (Albany
NY). 15:7187–7218. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gu JJ, Du TJ, Zhang LN, Zhou J, Gu X and
Zhu Y: Identification of ferroptosis-related genes in heart failure
induced by transverse aortic constriction. J Inflamm Res.
16:4899–4912. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Marian AJ: Molecular genetic basis of
hypertrophic cardiomyopathy. Circ Res. 128:1533–1553. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Madè A, Bibi A, Garcia-Manteiga JM,
Tascini AS, Piella SN, Tikhomirov R, Voellenkle C, Gaetano C,
Leszek P, Castelvecchio S, et al: circRNA-miRNA-mRNA deregulated
network in ischemic heart failure patients. Cells. 12:25782023.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wong LL, Wang J, Liew OW, Richards AM and
Chen YT: MicroRNA and heart failure. Int J Mol Sci. 17:5022016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Park JH and Kho C: MicroRNAs and calcium
signaling in heart disease. Int J Mol Sci. 22:105822021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Saad NS, Mashali MA, Repas SJ and Janssen
PML: Altering calcium sensitivity in heart failure: A crossroads of
disease etiology and therapeutic innovation. Int J Mol Sci.
24:175772023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hinton A Jr, Claypool SM, Neikirk K, Senoo
N, Wanjalla CN, Kirabo A and Williams CR: Mitochondrial structure
and function in human heart failure. Circ Res. 135:372–396. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xue P, Liu Y, Wang H, Huang J and Luo M:
miRNA-103-3p-Hlf regulates apoptosis and autophagy by targeting
hepatic leukaemia factor in heart failure. ESC Heart Fail.
10:3038–3045. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pagan LU, Gomes MJ, Martinez PF and Okoshi
MP: Oxidative stress and heart failure: Mechanisms, signalling
pathways, and therapeutics. Oxid Med Cell Longev. 2022:98295052022.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hanna A and Frangogiannis NG: Inflammatory
cytokines and chemokines as therapeutic targets in heart failure.
Cardiovasc Drugs Ther. 34:849–863. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Manolis AA, Manolis TA and Manolis AS:
Neurohumoral activation in heart failure. Int J Mol Sci.
24:154722023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cappola TP and Burke MF: Studying Heart
failure through the lens of gene regulation. Circ Heart Fail.
13:e0076472020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Levin MG, Tsao NL, Singhal P, Liu C, Vy
HMT, Paranjpe I, Backman JD, Bellomo TR, Bone WP, Biddinger KJ, et
al: Genome-wide association and multi-trait analyses characterize
the common genetic architecture of heart failure. Nat Commun.
13:69142022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tudurachi BS, Zăvoi A, Leonte A, Țăpoi L,
Ureche C, Bîrgoan SG, Chiuariu T, Anghel L, Radu R, Sascău RA and
Stătescu C: An update on MYBPC3 gene mutation in hypertrophic
cardiomyopathy. Int J Mol Sci. 24:105102023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Park J, Packard EA, Levin MG, Judy RL;
Regeneron Genetics Center; Damrauer SM, Day SM, Ritchie MD and
Rader DJ: A genome-first approach to rare variants in hypertrophic
cardiomyopathy genes MYBPC3 and MYH7 in a medical biobank. Hum Mol
Genet. 31:827–837. 2022. View Article : Google Scholar :
|
|
27
|
Akboua H, Eghbalzadeh K, Keser U, Wahlers
T and Paunel-Görgülü A: Impaired non-canonical transforming growth
factor-β signalling prevents profibrotic phenotypes in cultured
peptidylarginine deiminase 4-deficient murine cardiac fibroblasts.
J Cell Mol Med. 25:9674–9684. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Qian L, Xu H, Yuan R, Yun W and Ma Y:
Formononetin ameliorates isoproterenol induced cardiac fibrosis
through improving mitochondrial dysfunction. Biomed Pharmacother.
170:1160002024. View Article : Google Scholar
|
|
29
|
Roe AT, Frisk M and Louch WE: Targeting
cardiomyocyte Ca2+ homeostasis in heart failure. Curr Pharm Des.
21:431–448. 2015. View Article : Google Scholar :
|
|
30
|
Shah K, Seeley S, Schulz C, Fisher J and
Gururaja Rao S: Calcium channels in the heart: Disease states and
drugs. Cells. 11:9432022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Al-Hayali MA, Sozer V, Durmus S, Erdenen
F, Altunoglu E, Gelisgen R, Atukeren P, Atak PG and Uzun H:
Clinical value of circulating microribonucleic acids miR-1 and
miR-21 in evaluating the diagnosis of acute heart failure in
asymptomatic type 2 diabetic patients. Biomolecules. 9:1932019.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vilella-Figuerola A, Gallinat A, Escate R,
Mirabet S, Padró T and Badimon L: Systems biology in chronic heart
failure-identification of potential miRNA regulators. Int J Mol
Sci. 23:152262022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xu R, Wu J, Yang CJ, Kang L, Ji YY, Li C,
Ding ZW and Zou YZ: A circRNA-miRNA-mRNA network analysis
underlying pathogenesis of human heart failure. J Geriatr Cardiol.
20:350–360. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gallo G, Rubattu S and Volpe M:
Mitochondrial dysfunction in heart failure: From Pathophysiological
mechanisms to therapeutic opportunities. Int J Mol Sci.
25:26672024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
van Empel VPM, Bertrand ATA, Hofstra L,
Crijns HJ, Doevendans PA and De Windt LJ: Myocyte apoptosis in
heart failure. Cardiovasc Res. 67:21–29. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Guo X, Chen Y and Liu Q: Necroptosis in
heart disease: Molecular mechanisms and therapeutic implications. J
Mol Cell Cardiol. 169:74–83. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kang Y and Wang Q: Potential therapeutic
value of necroptosis inhibitor for the treatment of COVID-19. Eur J
Med Res. 27:2832022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lu LQ, Tian J, Luo XJ and Peng J:
Targeting the pathways of regulated necrosis: A potential strategy
for alleviation of cardio-cerebrovascular injury. Cell Mol Life
Sci. 78:63–78. 2021. View Article : Google Scholar
|
|
39
|
Zhang H and Dhalla NS: The role of
pro-inflammatory cytokines in the pathogenesis of cardiovascular
disease. Int J Mol Sci. 25:10822024. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bishopric NH, Andreka P, Slepak T and
Webster KA: Molecular mechanisms of apoptosis in the cardiac
myocyte. Curr Opin Pharmacol. 1:141–150. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tsutsui H, Kinugawa S and Matsushima S:
Oxidative stress and heart failure. Am J Physiol Heart Circ
Physiol. 301:H2181–H2190. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Khoynezhad A, Jalali Z and Tortolani AJ: A
synopsis of research in cardiac apoptosis and its application to
congestive heart failure. Tex Heart Inst J. 34:352–359.
2007.PubMed/NCBI
|
|
43
|
Paulus WJ and Zile MR: From systemic
inflammation to myocardial fibrosis: The heart failure with
preserved ejection fraction paradigm revisited. Circ Res.
128:1451–1467. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kjaer A and Hesse B: Heart failure and
neuroendocrine activation: Diagnostic, prognostic and therapeutic
perspectives. Clin Physiol. 21:661–672. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Blackwell DJ, Schmeckpeper J and Knollmann
BC: Animal models to study cardiac arrhythmias. Circ Res.
130:1926–1964. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Reißmann B, Rottner L, Rillig A and
Metzner A: Cardiac arrhythmia. MMW Fortschr Med. 163:62–71. 2021.In
German. View Article : Google Scholar
|
|
47
|
Fu DG: Cardiac arrhythmias: Diagnosis,
symptoms, and treatments. Cell Biochem Biophys. 73:291–296. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Paludan-Müller C, Vad OB, Stampe NK,
Diederichsen SZ, Andreasen L, Monfort LM, Fosbøl EL, Køber L,
Torp-Pedersen C, Svendsen JH and Olesen MS: Atrial fibrillation:
Age at diagnosis, incident cardiovascular events, and mortality.
Eur Heart J. 45:2119–2129. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Liu X, Zhang W, Luo J, Shi W, Zhang X, Li
Z, Qin X, Liu B and Wei Y: TRIM21 deficiency protects against
atrial inflammation and remodeling post myocardial infarction by
attenuating oxidative stress. Redox Biol. 62:1026792023. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Bossuyt J, Borst JM, Verberckmoes M,
Bailey LRJ, Bers DM and Hegyi B: Protein kinase D1 regulates
cardiac hypertrophy, potassium channel remodeling, and arrhythmias
in heart failure. J Am Heart Assoc. 11:e0275732022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Piccini JP: Atrial fibrillation and heart
failure: Too much talk and not enough action. JACC Clin
Electrophysiol. 9:581–582. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wang H, Chen Y, Zhao S, Wang X, Lu K and
Xiao H: Effect of Sox9 on TGF-β1-mediated atrial fibrosis. Acta
Biochim Biophys Sin (Shanghai). 53:1450–1458. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wolke C, Antileo E and Lendeckel U: WNT
signaling in atrial fibrillation. Exp Biol Med (Maywood).
246:1112–1120. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Huang M, Huiskes FG, de Groot NMS and
Brundel BJJM: The role of immune cells driving electropathology and
atrial fibrillation. Cells. 13:3112021. View Article : Google Scholar
|
|
55
|
Yokoyama T, Kuga T, Itoh Y, Otake S, Omata
C, Saitoh M and Miyazawa K: Smad2Δexon3 and Smad3 have distinct
properties in signal transmission leading to TGF-β-induced cell
motility. J Biol Chem. 299:1028202023. View Article : Google Scholar
|
|
56
|
Miyazawa K, Itoh Y, Fu H and Miyazono K:
Receptor-activated transcription factors and beyond: Multiple modes
of Smad2/3-dependent transmission of TGF-β signaling. J Biol Chem.
300:1072562024. View Article : Google Scholar
|
|
57
|
Hu HH, Chen DQ, Wang YN, Feng YL, Cao G,
Vaziri ND and Zhao YY: New insights into TGF-β/Smad signaling in
tissue fibrosis. Chem Biol Interact. 292:76–83. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Gao S, Li X, Jiang Q, Liang Q, Zhang F, Li
S, Zhang R, Luan J, Zhu J, Gu X, et al: PKM2 promotes pulmonary
fibrosis by stabilizing TGF-β1 receptor I and enhancing TGF-β1
signaling. Sci Adv. 8:eabo09872022. View Article : Google Scholar
|
|
59
|
Stolfi C, Troncone E, Marafini I and
Monteleone G: Role of TGF-beta and Smad7 in gut inflammation,
fibrosis and cancer. Biomolecules. 11:172020. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Derynck R and Zhang YE: Smad-dependent and
Smad-independent pathways in TGF-beta family signalling. Nature.
425:577–584. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Li X, Zhu F, Meng W, Zhang F, Hong J,
Zhang G and Wang F: CYP2J2/EET reduces vulnerability to atrial
fibrillation in chronic pressure overload mice. J Cell Mol Med.
24:862–874. 2020. View Article : Google Scholar
|
|
62
|
Wang D, Wang X, Yang T, Tian H, Su Y and
Wang Q: Long non-coding RNA Dancr affects myocardial fibrosis in
atrial fibrillation mice via the MicroRNA-146b-5p/Smad5 axis. Acta
Cardiol Sin. 39:841–853. 2023.PubMed/NCBI
|
|
63
|
Tian L, Wang Y and Jang YY: Wnt signaling
in biliary development, proliferation, and fibrosis. Exp Biol Med
(Maywood). 247:360–367. 2022. View Article : Google Scholar
|
|
64
|
Somanader DVN, Zhao P, Widdop RE and
Samuel CS: The involvement of the Wnt/β-catenin signaling cascade
in fibrosis progression and its therapeutic targeting by relaxin.
Biochem Pharmacol. 223:1161302024. View Article : Google Scholar
|
|
65
|
Roberts JD, Murphy NP, Hamilton RM,
Lubbers ER, James CA, Kline CF, Gollob MH, Krahn AD, Sturm AC, Musa
H, et al: Ankyrin-B dysfunction predisposes to arrhythmogenic
cardiomyopathy and is amenable to therapy. J Clin Invest.
129:3171–3184. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Lorenzon A, Calore M, Poloni G, De Windt
LJ, Braghetta P and Rampazzo A: Wnt/β-catenin pathway in
arrhythmogenic cardiomyopathy. Oncotarget. 8:60640–60655. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Lv X, Li J, Hu Y, Wang S, Yang C, Li C and
Zhong G: Overexpression of miR-27b-3p targeting Wnt3a regulates the
signaling pathway of Wnt/β-catenin and attenuates atrial fibrosis
in rats with atrial fibrillation. Oxid Med Cell Longev.
2019:57037642019. View Article : Google Scholar
|
|
68
|
Lai YJ, Tsai FC, Chang GJ, Chang SH, Huang
CC, Chen WJ and Yeh YH: miR-181b targets semaphorin 3A to mediate
TGF-β-induced endothelial-mesenchymal transition related to atrial
fibrillation. J Clin Invest. 132:e1425482022. View Article : Google Scholar
|
|
69
|
Zhang Z, Li L, Hu Z, Zhou L, Zhang Z,
Xiong Y and Yao Y: Causal effects between atrial fibrillation and
heart failure: Evidence from a bidirectional Mendelian
randomization study. BMC Med Genomics. 16:1872023. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Sagris M, Vardas EP, Theofilis P,
Antonopoulos AS, Oikonomou E and Tousoulis D: Atrial fibrillation:
Pathogenesis, predisposing factors, and genetics. Int J Mol Sci.
23:62021. View Article : Google Scholar
|
|
71
|
Husti Z, Varró A and Baczkó I:
Arrhythmogenic remodeling in the failing heart. Cells. 10:32032021.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Sun Z, Zhou D, Xie X, Wang S, Wang Z, Zhao
W, Xu H and Zheng L: Cross-talk between macrophages and atrial
myocytes in atrial fibrillation. Basic Res Cardiol. 111:632016.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Huiskes FG, Creemers EE and Brundel BJJM:
Dissecting the molecular mechanisms driving electropathology in
atrial fibrillation: Deployment of RNA sequencing and
transcriptomic analyses. Cells. 12:22422023. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Maury P, Sanchis K, Djouadi K, Cariou E,
Delasnerie H, Boveda S, Fournier P, Itier R, Mondoly P,
Voglimacci-Stephan opoli Q, et al: Catheter ablation of atrial
arrhythmias in cardiac amyloidosis: Impact on heart failure and
mortality. PLoS One. 19:e03017532024. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Lei M, Wu L, Terrar DA and Huang CL:
Modernized classification of cardiac antiarrhythmic drugs.
Circulation. 138:1879–1896. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Mankad P and Kalahasty G: Antiarrhythmic
drugs: Risks and benefits. Med Clin North Am. 103:821–834. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Romero G, Martin B, Gabris B and Salama G:
Relaxin suppresses atrial fibrillation, reverses fibrosis and
reduces inflammation in aged hearts. Biochem Pharmacol.
227:1164072024. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Martin B, Gabris B, Barakat AF, Henry BL,
Giannini M, Reddy RP, Wang X, Romero G and Salama G: Relaxin
reverses maladaptive remodeling of the aged heart through
Wnt-signaling. Sci Rep. 9:185452019. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Hao H, Yan S, Zhao X, Han X, Fang N, Zhang
Y, Dai C, Li W, Yu H, Gao Y, et al: Atrial myocyte-derived exosomal
microRNA contributes to atrial fibrosis in atrial fibrillation. J
Transl Med. 20:4072022. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Benali K, Khairy P, Hammache N, Petzl A,
Da Costa A, Verma A, Andrade JG and Macle L: Procedure-related
complications of catheter ablation for atrial fibrillation. J Am
Coll Cardiol. 81:2089–2099. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Zhang Z, Xiao Y, Dai Y, Lin Q and Liu Q:
Device therapy for patients with atrial fibrillation and heart
failure with preserved ejection fraction. Heart Fail Rev.
29:417–430. 2024. View Article : Google Scholar :
|
|
82
|
Li S, Wang Y, Yang W, Zhou D, Zhuang B, Xu
J, He J, Yin G, Fan X, Wu W, et al: Cardiac MRI risk stratification
for dilated cardiomyopathy with left ventricular ejection fraction
of 35% or higher. Radiology. 306:e2130592023. View Article : Google Scholar
|
|
83
|
Schultheiss HP, Fairweather D, Caforio
ALP, Escher F, Hershberger RE, Lipshultz SE, Liu PP, Matsumori A,
Mazzanti A, McMurray J and Priori SG: Dilated cardiomyopathy. Nat
Rev Dis Primers. 5:322019. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Orphanou N, Papatheodorou E and
Anastasakis A: Dilated cardiomyopathy in the era of precision
medicine: Latest concepts and developments. Heart Fail Rev.
27:1173–1191. 2022. View Article : Google Scholar
|
|
85
|
Liu M, Zhai L, Yang Z, Li S, Liu T, Chen
A, Wang L, Li Y, Li R, Li C, et al: Integrative proteomic analysis
reveals the cytoskeleton regulation and mitophagy difference
between ischemic cardiomyopathy and dilated cardiomyopathy. Mol
Cell Proteomics. 22:1006672023. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Wang E, Zhou R, Li T, Hua Y, Zhou K, Li Y,
Luo S and An Q: The molecular role of immune cells in dilated
cardiomyopathy. Medicina (Kaunas). 59:12462023. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Yuan S, Zhang X, Zhan J, Xie R, Fan J, Dai
B, Zhao Y, Yin Z, Liu Q, Wang DW, et al: Fibroblast-localized
lncRNA CFIRL promotes cardiac fibrosis and dysfunction in dilated
cardiomyopathy. Sci China Life Sci. 67:1155–1169. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Mado K, Chekulayev V, Shevchuk I, Puurand
M, Tepp K and Kaambre T: On the role of tubulin, plectin, desmin,
and vimentin in the regulation of mitochondrial energy fluxes in
muscle cells. Am J Physiol Cell Physiol. 316:C657–C667. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Zhang J, Cheng L, Li Z, Li H, Liu Y, Zhan
H, Xu H, Huang Y, Feng F and Li Y: Immune cells and related
cytokines in dilated cardiomyopathy. Biomed Pharmacother.
171:1161592024. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Cavusoglu Y, Tahmazov S, Murat S and Akay
OM: Immunoadsorption therapy in refractory heart failure patients
with dilated cardiomyopathy: A potential therapeutic option. Rev
Assoc Med Bras (1992). 69:90–96. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Zhong G, Chen C, Wu S, Chen J, Han Y, Zhu
Q, Xu M, Nie Q and Wang L: Mechanism of angiotensin-converting
enzyme inhibitors in the treatment of dilated cardiomyopathy based
on a protein interaction network and molecular docking. Cardiovasc
Diagn Ther. 13:534–549. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Tong X, Shen L, Zhou X, Wang Y, Chang S
and Lu S: Comparative efficacy of different drugs for the treatment
of dilated cardiomyopathy: A systematic review and network
meta-analysis. Drugs R D. 23:197–210. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Jiao M, Wang X, Liang Y, Yang Y, Gu Y,
Wang Z, Lv Z and Jin M: Effect of β-blocker therapy on the level of
soluble ST2 protein in pediatric dilated cardiomyopathy. Medicina
(Kaunas). 58:13392022. View Article : Google Scholar
|
|
94
|
Ferreira JP, Butler J, Zannad F,
Filippatos G, Schueler E, Steubl D, Zeller C, Januzzi JL, Pocock S,
Packer M and Anker SD: Mineralocorticoid receptor antagonists and
empagliflozin in patients with heart failure and preserved ejection
fraction. J Am Coll Cardiol. 79:1129–1137. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Eldemire R, Mestroni L and Taylor MRG:
Genetics of dilated cardiomyopathy. Annu Rev Med. 75:417–426. 2024.
View Article : Google Scholar :
|
|
96
|
Jordan E, Peterson L, Ai T, Asatryan B,
Bronicki L, Brown E, Celeghin R, Edwards M, Fan J, Ingles J, et al:
Evidence-based assessment of genes in dilated cardiomyopathy.
Circulation. 144:7–19. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Koga-Ikuta A, Fukushima S, Ishibashi-Ueda
H, Tadokoro N, Kakuta T, Watanabe T, Fukushima N, Suzuki K, Fukui T
and Fujita T: Immunocompetent cells in durable ventricular assist
device-implanted non-ischaemic dilated cardiomyopathy. Gen Thorac
Cardiovasc Surg. 70:685–693. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Dziekiewicz M, Banaszewski M, Kuć M and
Stępińska J: Intra-aortic balloon pump catheter insertion using a
novel left external iliac artery approach in a case of chronic
heart failure due to dilated cardiomyopathy. Am J Case Rep.
20:1826–1829. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Zhang X, Wei R, Wang X, Zhang W, Li M, Ni
T, Weng W and Li Q: The neutrophil-to-lymphocyte ratio is
associated with all-cause and cardiovascular mortality among
individuals with hypertension. Cardiovasc Diabetol. 23:1172024.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Messerli FH, Rimoldi SF and Bangalore S:
The transition from hypertension to heart failure: Contemporary
update. JACC Heart Fail. 5:543–551. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Ma J, Li Y, Yang X, Liu K, Zhang X, Zuo X,
Ye R, Wang Z, Shi R, Meng Q and Chen X: Signaling pathways in
vascular function and hypertension: Molecular mechanisms and
therapeutic interventions. Signal Transduct Target Ther. 8:1682023.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Konukoglu D and Uzun H: Endothelial
dysfunction and hypertension. Hypertension: From basic research to
clinical practice. 511–540. 2017.
|
|
103
|
Watson T, Goon PKY and Lip GYH:
Endothelial progenitor cells, endothelial dysfunction,
inflammation, and oxidative stress in hypertension. Antioxid Redox
Signal. 10:1079–1088. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Zhu N, Guo ZF, Kazama K, Yi B, Tongmuang
N, Yao H, Yang R, Zhang C, Qin Y, Han L and Sun J: Epigenetic
regulation of vascular smooth muscle cell phenotypic switch and
neointimal formation by PRMT5. Cardiovasc Res. 119:2244–2255. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Liard JF and Peters G: Role of the
retention of water and sodium in two types of experimental
renovascular hypertension in the rat. Pflugers Arch. 344:93–108.
1973. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Hu Y, Lin L, Zhang L, Li Y, Cui X, Lu M,
Zhang Z, Guan X, Zhang M, Hao J, et al: Identification of
circulating plasma proteins as a mediator of hypertension-driven
cardiac remodeling: A mediation mendelian randomization study.
Hypertension. 81:1132–1144. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Wang M, Han X, Yu T, Wang M, Luo W, Zou C,
Li X, Li G, Wu G, Wang Y and Liang G: OTUD1 promotes pathological
cardiac remodeling and heart failure by targeting STAT3 in
cardiomyocytes. Theranostics. 13:2263–2280. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Holopainen T, Räsänen M, Anisimov A,
Tuomainen T, Zheng W, Tvorogov D, Hulmi JJ, Andersson LC, Cenni B,
Tavi P, et al: Endothelial Bmx tyrosine kinase activity is
essential for myocardial hypertrophy and remodeling. Proc Natl Acad
Sci USA. 112:13063–13068. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Li L, Fu W, Gong X, Chen Z, Tang L, Yang
D, Liao Q, Xia X, Wu H, Liu C, et al: The role of G protein-coupled
receptor kinase 4 in cardiomyocyte injury after myocardial
infarction. Eur Heart J. 42:1415–1430. 2021. View Article : Google Scholar :
|
|
110
|
Bazgir F, Nau J, Nakhaei-Rad S, Amin E,
Wolf MJ, Saucerman JJ, Lorenz K and Ahmadian MR: The
microenvironment of the pathogenesis of cardiac hypertrophy. Cells.
12:17802023. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Nakamura M and Sadoshima J: Mechanisms of
physiological and pathological cardiac hypertrophy. Nat Rev
Cardiol. 15:387–407. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Bertaud A, Joshkon A, Heim X, Bachelier R,
Bardin N, Leroyer AS and Blot-Chabaud M: Signaling pathways and
potential therapeutic strategies in cardiac fibrosis. Int J Mol
Sci. 24:17562023. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Zhang W, Wang Q, Feng Y, Chen X, Yang L,
Xu M, Wang X, Li W, Niu X and Gao D: MicroRNA-26a protects the
heart against hypertension-induced myocardial fibrosis. J Am Heart
Assoc. 9:e0179702020. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Failer T, Amponsah-Offeh M, Neuwirth A,
Kourtzelis I, Subramanian P, Mirtschink P, Peitzsch M, Matschke K,
Tugtekin SM, Kajikawa T, et al: Developmental endothelial locus-1
protects from hypertension-induced cardiovascular remodeling via
immunomodulation. J Clin Invest. 132:e1261552022. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Rai R, Sun T, Ramirez V, Lux E, Eren M,
Vaughan DE and Ghosh AK: Acetyltransferase p300 inhibitor reverses
hypertension-induced cardiac fibrosis. J Cell Mol Med.
23:3026–3031. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Lv SL, Zeng ZF, Gan WQ, Wang WQ, Li TG,
Hou YF, Yan Z, Zhang RX and Yang M: Lp-PLA2 inhibition prevents Ang
II-induced cardiac inflammation and fibrosis by blocking macrophage
NLRP3 inflammasome activation. Acta Pharmacol Sin. 42:2016–2032.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Johnson MT, Gudlur A, Zhang X, Xin P,
Emrich SM, Yoast RE, Courjaret R, Nwokonko RM, Li W, Hempel N, et
al: L-type Ca2+ channel blockers promote vascular
remodeling through activation of STIM proteins. Proc Natl Acad Sci
USA. 117:17369–17380. 2020. View Article : Google Scholar
|
|
118
|
Zhang Y, Murugesan P, Huang K and Cai H:
NADPH oxidases and oxidase crosstalk in cardiovascular diseases:
novel therapeutic targets. Nat Rev Cardiol. 17:170–194. 2020.
View Article : Google Scholar
|
|
119
|
Nardoianni G, Pala B, Scoccia A, Volpe M,
Barbato E and Tocci G: Systematic review article: New drug
strategies for treating resistant hypertension-the importance of a
mechanistic, personalized approach. High Blood Press Cardiovasc
Prev. 31:99–112. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Zhang ZY, Yu YL, Asayama K, Hansen TW,
Maestre GE and Staessen JA: Starting antihypertensive drug
treatment with combination therapy: Controversies in
hypertension-con side of the argument. Hypertension. 77:788–798.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Maron BJ, Desai MY, Nishimura RA, Spirito
P, Rakowski H, Towbin JA, Dearani JA, Rowin EJ, Maron MS and
Sherrid MV: Management of hypertrophic cardiomyopathy: JACC
state-of-the-art review. J Am Coll Cardiol. 79:390–414. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Maron BA, Wang RS, Carnethon MR, Rowin EJ,
Loscalzo J, Maron BJ and Maron MS: What causes hypertrophic
cardiomyopathy? Am J Cardiol. 179:74–82. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Cirino AL, Channaoui N and Ho C:
Nonsyndromic hypertrophic cardiomyopathy overview.
GeneReviews® [Internet]. Adam MP, Feldman J, Mirzaa GM,
Pagon RA, Wallace SE and Amemiya A: University of Washington;
Seattle, WA: 1993
|
|
124
|
Bazan SGZ, Oliveira GO, Silveira CFDSMPD,
Reis FM, Malagutte KNDS, Tinasi LSN, Bazan R, Hueb JC and Okoshi K:
Hypertrophic cardiomyopathy: A review. Arq Bras Cardiol.
115:927–935. 2020.In English, Portuguese. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Homburger JR, Green EM, Caleshu C, Sunitha
MS, Taylor RE, Ruppel KM, Metpally RP, Colan SD, Michels M, Day SM,
et al: Multidimensional structure-function relationships in human
β-cardiac myosin from population-scale genetic variation. Proc Natl
Acad Sci USA. 113:6701–6706. 2016. View Article : Google Scholar
|
|
126
|
Lin LR, Hu XQ, Lu LH, Dai JZ, Lin NN, Wang
RH, Xie ZX and Chen XM: MicroRNA expression profiles in familial
hypertrophic cardiomyopathy with myosin-binding protein C3 (MYBPC3)
gene mutations. BMC Cardiovasc Disord. 22:2782022. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Parbhudayal RY, Harms HJ, Michels M, van
Rossum AC, Germans T and van der Velden J: Increased myocardial
oxygen consumption precedes contractile dysfunction in hypertrophic
cardiomyopathy caused by pathogenic TNNT2 gene variants. J Am Heart
Assoc. 9:e0153162020. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Fahed AC, Nemer G, Bitar FF, Arnaout S,
Abchee AB, Batrawi M, Khalil A, Abou Hassan OK, DePalma SR,
McDonough B, et al: Founder mutation in N terminus of cardiac
troponin i causes malignant hypertrophic cardiomyopathy. Circ Genom
Precis Med. 13:444–452. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Schulz EM, Wilder T, Chowdhury SA, Sheikh
HN, Wolska BM, Solaro RJ and Wieczorek DF: Decreasing tropomyosin
phosphorylation rescues tropomyosin-induced familial hypertrophic
cardiomyopathy. J Biol Chem. 288:28925–28935. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Wijnker PJM and van der Velden J:
Mutation-specific pathology and treatment of hypertrophic
cardiomyopathy in patients, mouse models and human engineered heart
tissue. Biochim Biophys Acta Mol Basis Dis. 1866:1657742020.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Enriquez AD and Goldman ME: Management of
hypertrophic cardiomyopathy. Ann Glob Health. 80:35–45. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Lehman SJ, Crocini C and Leinwand LA:
Targeting the sarcomere in inherited cardiomyopathies. Nat Rev
Cardiol. 19:353–363. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Pradeep R, Akram A, Proute MC, Kothur NR,
Georgiou P, Serhiyenia T, Shi W, Kerolos ME and Mostafa JA:
Understanding the genetic and molecular basis of familial
hypertrophic cardiomyopathy and the current trends in gene therapy
for its management. Cureus. 13:e175482021.PubMed/NCBI
|
|
134
|
Liu T, Hao Y, Zhang Z, Zhou H, Peng S,
Zhang D, Li K, Chen Y and Chen M: Advanced cardiac patches for the
treatment of myocardial infarction. Circulation. 149:2002–2020.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Golforoush P, Yellon DM and Davidson SM:
Mouse models of atherosclerosis and their suitability for the study
of myocardial infarction. Basic Res Cardiol. 115:732020. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Jiang H, Fang T and Cheng Z: Mechanism of
heart failure after myocardial infarction. J Int Med Res.
51:30006052312025732023. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Jenča D, Melenovský V, Stehlik J, Staněk
V, Kettner J, Kautzner J, Adámková V and Wohlfahrt P: Heart failure
after myocardial infarction: Incidence and predictors. ESC Heart
Fail. 8:222–237. 2021. View Article : Google Scholar
|
|
138
|
Feng R, Wang D, Li T, Liu X, Peng T, Liu
M, Ren G, Xu H, Luo H, Lu D, et al: Elevated SLC40A1 impairs
cardiac function and exacerbates mitochondrial dysfunction,
oxidative stress, and apoptosis in ischemic myocardia. Int J Biol
Sci. 20:414–432. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Dharmakumar R, Nair AR, Kumar A and
Francis J: Myocardial infarction and the fine balance of iron. JACC
Basic Transl Sci. 6:581–583. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Zhao WK, Zhou Y, Xu TT and Wu Q:
Ferroptosis: Opportunities and challenges in myocardial
ischemia-reperfusion injury. Oxid Med Cell Longev.
2021:99296872021. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Marunouchi T, Onda S, Kurasawa M and
Tanonaka K: Angiotensin II is involved in MLKL activation during
the development of heart failure following myocardial infarction in
rats. Biol Pharm Bull. 47:809–817. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Santagostino SF, Assenmacher CA, Tarrant
JC, Adedeji AO and Radaelli E: Mechanisms of regulated cell death:
Current perspectives. Vet Pathol. 58:596–623. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Li A, Gao M, Liu B, Qin Y, Chen L, Liu H,
Wu H and Gong G: Mitochondrial autophagy: Molecular mechanisms and
implications for cardiovascular disease. Cell Death Dis.
13:4442022. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Held PH, Yusuf S and Furberg CD: Calcium
channel blockers in acute myocardial infarction and unstable
angina: An overview. BMJ. 299:1187–1192. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Makarewich CA, Zhang H, Davis J, Correll
RN, Trappanese DM, Hoffman NE, Troupes CD, Berretta RM, Kubo H,
Madesh M, et al: Transient receptor potential channels contribute
to pathological structural and functional remodeling after
myocardial infarction. Circ Res. 115:567–580. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Cui T, Liu W, Yu C, Ren J, Li Y, Shi X, Li
Q and Zhang J: Protective effects of allicin on acute myocardial
infarction in rats via hydrogen sulfide-mediated regulation of
coronary arterial vasomotor function and myocardial calcium
transport. Front Pharmacol. 12:7522442022. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Pietrzykowski Ł, Michalski P, Kosobucka A,
Kasprzak M, Fabiszak T, Stolarek W, Siller-Matula JM and Kubica A:
Medication adherence and its determinants in patients after
myocardial infarction. Sci Rep. 10:120282020. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Heart Outcomes Prevention Evaluation Study
Investigators; Yusuf S, Sleight P, Pogue J, Bosch J, Davies R and
Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor,
ramipril, on cardiovascular events in high-risk patients. N Engl J
Med. 342:145–153. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Khan SU, Singh M, Valavoor S, Khan MU,
Lone AN, Khan MZ, Khan MS, Mani P, Kapadia SR, Michos ED, et al:
Dual antiplatelet therapy after percutaneous coronary intervention
and drug-eluting stents: A systematic review and network
meta-analysis. Circulation. 142:1425–1436. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Yandrapalli S, Andries G, Gupta S, Dajani
AR and Aronow WS: Investigational drugs for the treatment of acute
myocardial infarction: Focus on antiplatelet and anticoagulant
agents. Expert Opin Investig Drugs. 28:223–234. 2019. View Article : Google Scholar
|
|
151
|
AIM-HIGH Investigators; Boden WE,
Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P,
Koprowicz K, McBride R, Teo K and Weintraub W: Niacin in patients
with low HDL cholesterol levels receiving intensive statin therapy.
N Engl J Med. 365:2255–2267. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Tsai IT and Sun CK: Stem cell therapy
against ischemic heart disease. Int J Mol Sci. 25:37782024.
View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Broch K, Anstensrud AK, Woxholt S, Sharma
K, Tøllefsen IM, Bendz B, Aakhus S, Ueland T, Amundsen BH, Damås
JK, et al: Randomized trial of interleukin-6 receptor inhibition in
patients with acute ST-segment elevation myocardial infarction. J
Am Coll Cardiol. 77:1845–1855. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Shi S, Chen Y, Luo Z, Nie G and Dai Y:
Role of oxidative stress and inflammation-related signaling
pathways in doxorubicin-induced cardiomyopathy. Cell Commun Signal.
21:612023. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Ye X, Li Y, Lv B, Qiu B, Zhang S, Peng H,
Kong W, Tang C, Huang Y, Du J and Jin H: Endogenous hydrogen
sulfide persulfidates caspase-3 at cysteine 163 to inhibit
doxorubicin-induced cardiomyocyte apoptosis. Oxid Med Cell Longev.
2022:61537722022. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Gammella E, Recalcati S, Rybinska I,
Buratti P and Cairo G: Iron-induced damage in cardiomyopathy:
Oxidative-dependent and independent mechanisms. Oxid Med Cell
Longev. 2015:2301822015. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Cheng CF and Lian WS: Prooxidant
mechanisms in iron overload cardiomyopathy. Biomed Res Int.
2013:7405732013. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Fatmi A, Saadi W, Beltrán-García J,
García-Giménez JL and Pallardó FV: The endothelial glycocalyx and
neonatal sepsis. Int J Mol Sci. 24:3642022. View Article : Google Scholar
|
|
159
|
Carthy CM, Yang D, Anderson DR, Wilson JE
and McManus BM: Myocarditis as systemic disease: New perspectives
on pathogenesis. Clin Exp Pharmacol Physiol. 24:997–1003. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Lasrado N and Reddy J: An overview of the
immune mechanisms of viral myocarditis. Rev Med Virol. 30:1–14.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Dimitropoulos G, Tahrani AA and Stevens
MJ: Cardiac autonomic neuropathy in patients with diabetes
mellitus. World J Diabetes. 5:17–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Lin S, Dai S, Lin J, Liang X, Wang W,
Huang W, Ye B and Hong X: Oridonin relieves angiotensin II-induced
cardiac remodeling via inhibiting GSDMD-mediated inflammation.
Cardiovasc Ther. 2022:31679592022. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Chen S, Huang Z, Liang Y, Zhao X,
Aobuliksimu X, Wang B, He Y, Kang Y, Huang H, Li Q, et al:
Five-year mortality of heart failure with preserved, mildly
reduced, and reduced ejection fraction in a 4880 Chinese cohort.
ESC Heart Fail. 9:2336–2347. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Liu M, López de Juan Abad B and Cheng K:
Cardiac fibrosis: Myofibroblast-mediated pathological regulation
and drug delivery strategies. Adv Drug Deliv Rev. 173:504–519.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Ravassa S, López B, Treibel TA, San José
G, Losada-Fuentenebro B, Tapia L, Bayés-Genís A, Díez J and
González A: Cardiac Fibrosis in heart failure: Focus on
non-invasive diagnosis and emerging therapeutic strategies. Mol
Aspects Med. 93:1011942023. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Martin TG, Juarros MA and Leinwand LA:
Regression of cardiac hypertrophy in health and disease: Mechanisms
and therapeutic potential. Nat Rev Cardiol. 20:347–363. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Su Z, Yang Z, Xu Y, Chen Y and Yu Q:
Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol
Cancer. 14:482015. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Dong Y, Liu C, Zhao Y, Ponnusamy M, Li P
and Wang K: Role of noncoding RNAs in regulation of cardiac cell
death and cardiovascular diseases. Cell Mol Life Sci. 75:291–300.
2018. View Article : Google Scholar
|
|
169
|
Cai K, Jiang H, Zou Y, Song C, Cao K, Chen
S, Wu Y, Zhang Z, Geng D, Zhang N, et al: Programmed death of
cardiomyocytes in cardiovascular disease and new therapeutic
approaches. Pharmacol Res. 206:1072812024. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Chiong M, Wang ZV, Pedrozo Z, Cao DJ,
Troncoso R, Ibacache M, Criollo A, Nemchenko A, Hill JA and
Lavandero S: Cardiomyocyte death: Mechanisms and translational
implications. Cell Death Dis. 2:e2442011. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Topriceanu CC, Pereira AC, Moon JC, Captur
G and Ho CY: Meta-analysis of penetrance and systematic review on
transition to disease in genetic hypertrophic cardiomyopathy.
Circulation. 149:107–123. 2024. View Article : Google Scholar :
|
|
172
|
Ye C, Zheng F, Wu N, Zhu GQ and Li XZ:
Extracellular vesicles in vascular remodeling. Acta Pharmacol Sin.
43:2191–2201. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Jordan-Rios A, Cannatà A, Bromage D and
McDonagh T: Challenges in the implementation of medical therapy in
heart failure. JACC Heart Fail. 11:607–609. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Pacesa M, Pelea O and Jinek M: Past,
present, and future of CRISPR genome editing technologies. Cell.
187:1076–1100. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Xiao Y, Zhao J, Tuazon JP, Borlongan CV
and Yu G: MicroRNA-133a and myocardial infarction. Cell Transplant.
28:831–838. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Reichart D, Newby GA, Wakimoto H, Lun M,
Gorham JM, Curran JJ, Raguram A, DeLaughter DM, Conner DA,
Marsiglia JDC, et al: Efficient in vivo genome editing prevents
hypertrophic cardiomyopathy in mice. Nat Med. 29:412–421. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Morris KV and Mattick JS: The rise of
regulatory RNA. Nat Rev Genet. 15:423–437. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Shim JS, Song WJ and Morice AH:
Drug-induced cough. Physiol Res. 69(Suppl 1): S81–S92. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Wong GW and Wright JM: Blood pressure
lowering efficacy of nonselective beta-blockers for primary
hypertension. Cochrane Database Syst Rev. 2014:CD0074522024.
|
|
180
|
Cheng CJ, Rodan AR and Huang CL: Emerging
targets of diuretic therapy. Clin Pharmacol Ther. 102:420–435.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Haley KE, Almas T, Shoar S, Shaikh S,
Azhar M, Cheema FH and Hameed A: The role of anti-inflammatory
drugs and nanoparticle-based drug delivery models in the management
of ischemia-induced heart failure. Biomed Pharmacother.
142:1120142021. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Pala R, Anju VT, Dyavaiah M, Busi S and
Nauli SM: Nanoparticle-mediated drug delivery for the treatment of
cardiovascular diseases. Int J Nanomedicine. 15:3741–3769. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Qiu R, Han S, Wei X, Zhong C, Li M, Hu J,
Wang P, Zhao C, Chen J and Shang H: Development of a core outcome
set for the benefits and adverse events of acute heart failure in
clinical trials of traditional Chinese medicine and western
medicine: A study protocol. Front Med (Lausanne). 8:6770682021.
View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Chen X, Ma Y, Li J, Yao L, Gui M, Lu B,
Zhou X, Wang M and Fu D: The efficacy of ginseng-containing
traditional Chinese medicine in patients with acute decompensated
heart failure: A systematic review and meta-analysis. Front
Pharmacol. 13:10830012023. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Ji MY, Bo A, Yang M, Xu JF, Jiang LL, Zhou
BC and Li MH: The pharmacological effects and health benefits of
platycodon grandiflorus-a medicine food homology species. Foods.
9:1422020. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Tang MM, Zhao ST, Li RQ and Hou W:
Therapeutic mechanisms of ginseng in coronary heart disease. Front
Pharmacol. 14:12710292023. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Yang L, Jiang H, Wang S, Hou A, Man W,
Zhang J, Guo X, Yang B, Kuang H and Wang Q: Discovering the major
antitussive, expectorant, and anti-inflammatory bioactive
constituents in Tussilago farfara L. based on the spectrum-effect
relationship combined with chemometrics. Molecules. 25:6202020.
View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Tan D, Tseng HHL, Zhong Z, Wang S, Vong CT
and Wang Y: Glycyrrhizic acid and its derivatives: Promising
candidates for the management of type 2 diabetes mellitus and its
complications. Int J Mol Sci. 23:109882022. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Feng Q, Ling L, Yuan H, Guo Z and Ma J:
Ginsenoside Rd: A promising target for ischemia-reperfusion injury
therapy (A mini review). Biomed Pharmacother. 171:1161112024.
View Article : Google Scholar : PubMed/NCBI
|
|
190
|
MacRitchie N and Maffia P: Light sheet
fluorescence microscopy for quantitative three-dimensional imaging
of vascular remodelling. Cardiovasc Res. 117:348–350. 2021.
View Article : Google Scholar :
|
|
191
|
Yu B, Lu Q, Li J, Cheng X, Hu H, Li Y, Che
T, Hua Y, Jiang H, Zhang Y, et al: Cryo-EM structure of human HCN3
channel and its regulation by cAMP. J Biol Chem. 300:1072882024.
View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Li H, Zhang X, Wang F, Zhou L, Yin Z, Fan
J, Nie X, Wang P, Fu XD, Chen C and Wang DW: MicroRNA-21 lowers
blood pressure in spontaneous hypertensive rats by upregulating
mitochondrial translation. Circulation. 134:734–751. 2016.
View Article : Google Scholar : PubMed/NCBI
|
